IIN IntriCon

IntriCon Announces Appointment of Craig Sandbulte as Vice President of Quality and Regulatory Affairs; Succeeds Greg Gruenhagen Upon Retirement

IntriCon Announces Appointment of Craig Sandbulte as Vice President of Quality and Regulatory Affairs; Succeeds Greg Gruenhagen Upon Retirement

ARDEN HILLS, Minn., Sept. 12, 2019 (GLOBE NEWSWIRE) -- IntriCon Corporation (NASDAQ: IIN), a designer, developer, manufacturer and distributor of miniature and micro-miniature body-worn devices, today announced Craig Sandbulte has been appointed VP of Quality and Regulatory Affairs. He assumes the role following the retirement of Greg Gruenhagen, effective October 1, 2019.

“We are delighted to welcome Craig to the IntriCon team,” said Mark Gorder, President and Chief Executive Officer at IntriCon. “I am confident that his extensive experience in the medical device industry will generate important insights and lead to the continuous advancement of our quality management systems, as well as our expanding need for international regulatory affairs.”

Mr. Sandbulte brings more than 20 years of experience working in various quality roles within the medical device industry, most recently as Vice President of Global Quality Assurance at Cantel Medical. In that role, he delivered quality assurance support for global manufacturing operations and held responsibility for the execution of compliance with domestic regulatory standards, global policies, international law and guidelines. Previously, he held leadership positions with increasing responsibility at Medivators, a Cantel Medical Company, culminating in a role as Vice President of Quality Assurance.  

Mr. Sandbulte holds a Master of Science degree in manufacturing systems from the University of St. Thomas and a Bachelor of Science degree in Manufacturing Engineering from the University of Wisconsin-Stout.

Commenting on Mr. Gruenhagen’s retirement, Gorder highlighted, “Greg has been a tremendous asset and important member of our team during his three-decade tenure at IntriCon. His leadership has been instrumental in our ability to achieve the necessary approvals for our many class I, II and III medical devices. On behalf of everyone at the company, we wish him all the best in his retirement.”

About IntriCon Corporation

Headquartered in Arden Hills, Minn., IntriCon Corporation designs, develops and manufactures miniature and micro-miniature body-worn devices. These advanced products help medical, healthcare and professional communications companies meet the rising demand for smaller, more intelligent and better-connected devices. IntriCon has facilities in the United States, Asia and Europe. The company’s common stock trades under the symbol “IIN” on the NASDAQ Global Market. For more information about IntriCon, visit .

Investor Relations Contact                                                              

Leigh Salvo                                   

(415) 937-5404    

 

EN
12/09/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IntriCon

 PRESS RELEASE

Intricon Announces Completion of Acquisition by an Affiliate of Altari...

Intricon Announces Completion of Acquisition by an Affiliate of Altaris Capital Partners Investment by Altaris Supports Intricon’s Ability to Deliver Innovative Solutions and Service to its Customers ARDEN HILLS, Minn., May 24, 2022 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ: IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced the completion of its acquisition by funds affiliated with Altaris Capital Partners, LLC (toget...

 PRESS RELEASE

Intricon Reports Fourth Quarter and Full Year 2021 Results

Intricon Reports Fourth Quarter and Full Year 2021 Results ARDEN HILLS, Minn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ: IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced financial results for its fourth quarter and year ended December 31, 2021. Fourth Quarter Highlights: Revenue of $32.2 million compared to $30.3 million in the prior year period Diabetes revenue increased 2% compared to the prior year...

 PRESS RELEASE

Intricon Enters into Agreement to be Acquired by an Affiliate of Altar...

Intricon Enters into Agreement to be Acquired by an Affiliate of Altaris Capital Partners for $241 Million Intricon Shareholders to Receive $24.25 Per Share in Cash ARDEN HILLS, Minn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ: IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced that it has entered into a definitive agreement whereby an affiliate of Altaris Capital Partners, LLC (collectively with its affi...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Tables: January 29, 2022

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Daily Ratings Report: January 24, 2022

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ResearchPool Subscriptions

Get the most out of your insights

Get in touch